[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100396905":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":28,"centralContacts":33,"locations":43,"responsibleParty":208,"collaborators":210,"id":213,"slug":12,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":214,"sex":220,"minAge":221,"maxAge":12,"enrollmentInfo":222,"targetDuration":12,"studyType":225,"phases":226,"briefSummary":228,"conditions":229,"keywords":12,"overallStatus":46,"whyStopped":12,"lastUpdateSubmitDate":231,"lastUpdatePostDateStruct":232,"startDateStruct":235,"completionDateStruct":237,"leadSponsor":239,"locationsCount":240},{"fullName":5,"class":6},"Ottawa Hospital Research Institute","OTHER",[8,13],{"label":9,"type":10,"description":11,"interventionNames":12},"Prophylactic Platelet Transfusion","NO_INTERVENTION","Patients allocated to the prophylactic platelet transfusion group will receive a platelet transfusion when the measured platelet count is less than 10 x 109\u002FL.",null,{"label":14,"type":15,"description":16,"interventionNames":17},"Prophylactic Tranexamic Acid","EXPERIMENTAL","Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.",[18],"Drug: Tranexamic Acid",[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":25},"DRUG","Tranexamic Acid","Patients allocated to the prophylactic Tranexamic Acid group will receive a standardized routine oral or intravenous dose of Tranexamic Acid 1 gram three times daily.\n\nTranexamic Acid will start when Platelet count is less than 50 x 109\u002FL and continue until platelet engraftment. Patients in this group will not receive routine prophylactic platelet transfusions. Subjects unable to swallow oral Tranexamic Acid pills may have the tablets crushed, administered via nasogastric (NG) tube or the medication will be administered intravenously.",[14],[26,27],"SteriMax Inc.","Cyclokapron®",[29],{"name":30,"affiliation":31,"role":32},"Alan Tinmouth, MD","The Ottawa Hospital","PRINCIPAL_INVESTIGATOR",[34,40],{"name":35,"role":36,"phone":37,"phoneExt":38,"email":39},"Sohail Robert, RN","CONTACT","613-737-8899","71892","sorobert@ohri.ca",{"name":30,"role":36,"phone":37,"phoneExt":41,"email":42},"73914","atinmouth@ohri.ca",[44,64,77,91,100,112,128,144,156,173,183,195],{"facility":45,"status":46,"city":47,"state":48,"zip":49,"country":50,"countryCode":51,"cosmosGeoPoint":52,"geoPoint":57,"contacts":58},"Tom Baker Cancer Centre","RECRUITING","Calgary","Alberta","T2N4N2","Canada","CA",{"type":53,"coordinates":54},"Point",[55,56],-114.08529,51.05011,{"lat":56,"lon":55},[59,63],{"name":60,"role":36,"phone":61,"phoneExt":12,"email":62},"Jason Tay, MD","403-944-1880","Jason.Tay@ahs.ca",{"name":60,"role":32,"phone":12,"phoneExt":12,"email":12},{"facility":65,"status":46,"city":66,"state":48,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":67,"geoPoint":71,"contacts":72},"Cross Cancer Institute","Edmonton",{"type":53,"coordinates":68},[69,70],-113.46871,53.55014,{"lat":70,"lon":69},[73,75],{"name":74,"role":36,"phone":12,"phoneExt":12,"email":12},"Irwindeep Sandhu, MD",{"name":12,"role":36,"phone":12,"phoneExt":12,"email":76},"irwindeep.sandhu2@albertahealthservices.ca",{"facility":78,"status":46,"city":79,"state":80,"zip":81,"country":50,"countryCode":51,"cosmosGeoPoint":82,"geoPoint":86,"contacts":87},"Eastern Regional Health Authority","St. John's","Newfoundland and Labrador","A1B 3V6",{"type":53,"coordinates":83},[84,85],-52.70931,47.56494,{"lat":85,"lon":84},[88],{"name":89,"role":36,"phone":12,"phoneExt":12,"email":90},"David Jones, MD","Davidm.jones@easternhealth.ca",{"facility":92,"status":93,"city":79,"state":80,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":94,"geoPoint":96,"contacts":97},"Memorial University","NOT_YET_RECRUITING",{"type":53,"coordinates":95},[84,85],{"lat":85,"lon":84},[98],{"name":99,"role":36,"phone":12,"phoneExt":12,"email":12},"Kirsty Tompkins, MD",{"facility":101,"status":93,"city":102,"state":103,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":104,"geoPoint":108,"contacts":109},"Dalhousie University","Halifax","Nova Scotia",{"type":53,"coordinates":105},[106,107],-63.57688,44.64269,{"lat":107,"lon":106},[110],{"name":111,"role":36,"phone":12,"phoneExt":12,"email":12},"Mahmood El-Sawy, MD",{"facility":113,"status":46,"city":114,"state":115,"zip":116,"country":50,"countryCode":51,"cosmosGeoPoint":117,"geoPoint":121,"contacts":122},"Hamilton Health Sciences - Juravinski Hospital and Cancer Centre","Hamilton","Ontario","L8V 1C3",{"type":53,"coordinates":118},[119,120],-79.84963,43.25011,{"lat":120,"lon":119},[123,127],{"name":124,"role":36,"phone":125,"phoneExt":126,"email":12},"Kylie Lepic, MD","905 521-2100","62491",{"name":124,"role":32,"phone":12,"phoneExt":12,"email":12},{"facility":129,"status":46,"city":130,"state":115,"zip":131,"country":50,"countryCode":51,"cosmosGeoPoint":132,"geoPoint":136,"contacts":137},"London Health Sciences Centre","London","N6A5W9",{"type":53,"coordinates":133},[134,135],-81.23304,42.98339,{"lat":135,"lon":134},[138,143],{"name":139,"role":36,"phone":140,"phoneExt":141,"email":142},"Anargyros Xenocostas, MD","519-685-8500","58631","Anargyros.Xenocostas@lhsc.on.ca",{"name":139,"role":32,"phone":12,"phoneExt":12,"email":12},{"facility":31,"status":46,"city":145,"state":115,"zip":146,"country":50,"countryCode":51,"cosmosGeoPoint":147,"geoPoint":151,"contacts":152},"Ottawa","K1H8L6",{"type":53,"coordinates":148},[149,150],-75.69812,45.41117,{"lat":150,"lon":149},[153,154],{"name":30,"role":36,"phone":37,"phoneExt":41,"email":42},{"name":155,"role":32,"phone":12,"phoneExt":12,"email":12},"Alan Tinmouth, MD MSc RCPSC",{"facility":157,"status":46,"city":158,"state":115,"zip":159,"country":50,"countryCode":51,"cosmosGeoPoint":160,"geoPoint":164,"contacts":165},"Niagara Health System","St. Catharines","L2S 0A9",{"type":53,"coordinates":161},[162,163],-79.24267,43.17126,{"lat":163,"lon":162},[166,171],{"name":167,"role":36,"phone":168,"phoneExt":169,"email":170},"Ramsha Faisal","905-378-4647","44266","Ramsha.faisal@niagarahealth.on.ca",{"name":172,"role":32,"phone":12,"phoneExt":12,"email":12},"Mohammad Refaei, MD",{"facility":174,"status":175,"city":176,"state":115,"zip":177,"country":50,"countryCode":51,"cosmosGeoPoint":178,"geoPoint":182,"contacts":12},"Princess Margaret Cancer Centre","WITHDRAWN","Toronto","M5G 2M9",{"type":53,"coordinates":179},[180,181],-79.39864,43.70643,{"lat":181,"lon":180},{"facility":184,"status":93,"city":185,"state":186,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":187,"geoPoint":191,"contacts":192},"Hopital Maisonneuve-Rosemont","Montreal","Quebec",{"type":53,"coordinates":188},[189,190],-73.58781,45.50884,{"lat":190,"lon":189},[193],{"name":194,"role":36,"phone":12,"phoneExt":12,"email":12},"Silvy Lachance, MD",{"facility":196,"status":46,"city":197,"state":198,"zip":12,"country":50,"countryCode":51,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"Saskatchewan Cancer Agency","Saskatoon","Saskatchewan",{"type":53,"coordinates":200},[201,202],-106.66892,52.13238,{"lat":202,"lon":201},[205],{"name":206,"role":36,"phone":12,"phoneExt":12,"email":207},"Mohamed Elementary, MD","mohamed.elemary@saskcancer.ca",{"type":209,"investigatorFullName":12,"investigatorTitle":12,"investigatorAffiliation":12,"oldNameTitle":12,"oldOrganization":12},"SPONSOR",[211],{"name":212,"class":6},"Alberta Cancer Foundation","100396905",false,"NCT04448184","Platelet Transfusions in Hematopoietic Stem Cell Transplantation (The PATH III Trial)","Platelet Transfusions in Hematopoietic Stem Cell Transplantation - The PATH Phase III Trial","PATH","Inclusion Criteria:\n\n1. Adults 18 years or older undergoing ASCT for a hematologic malignancy\n2. Patients providing written informed consent prior to starting transplantation\n\nExclusion Criteria:\n\n1. A previous WHO grade 2, 3 or 4 bleeding event within the past year\n2. A previous or current unprovoked thrombotic event defined as a pulmonary embolism, deep vein thrombosis, cerebral thrombosis\n3. A current provoked thrombotic event (e.g. catheter-related thrombosis) within last month and\u002For still requiring anticoagulant treatment.\n4. A requirement for therapeutic anticoagulant or anti-platelet drugs during ASCT\n5. Active angina (chest pain of presumed cardiac origin either at rest or with activity)\n6. Current or previous (within 2 weeks) urinary tract bleeding\n7. An inherited hemostatic or thrombotic disorder\n8. Coagulopathy defined as a prothrombin time '\u002FInternational Normalization Ratio (INR) or activated partial thromboplastin time more than 1.5 times the upper limit of normal or fibrinogen less than 2 g\u002FL\n9. Previously documented history of refractoriness to platelet transfusion secondary to HLA antibodies (Refractoriness is defined as 2 consecutive ABO matched platelet transfusions with platelet increment of \\\u003C 7.5 and the presence of anti-HLA antibodies)\n10. Significant renal impairment (creatinine more than 1.5 times the upper limit of normal or a eGFR less than 0.5 mL\u002Fmin\u002F1.78m2)\n11. Pregnant or breast-feeding\n12. Unwilling or unable to provide informed consent\n13. Participant has acquired disturbances to his\u002Fher colour vision (does not apply to congenital colour blindness)\n14. Participant has known sensitivity or allergy to Tranexamic Acid or any of its ingredients","ALL","18 Years",{"count":223,"type":224},662,"ESTIMATED","INTERVENTIONAL",[227],"PHASE3","It is hypothesized that a strategy using prophylactic oral and intravenous Tranexamic Acid (TXA) with therapeutic platelet transfusions (if required) is safe and more effective than prophylactic platelet transfusions in patients undergoing an autologous hematopoietic stem cell transplantation (ASCT).",[230],"Hematologic Neoplasms","2026-01-06",{"date":233,"type":234},"2026-01-08","ACTUAL",{"date":236,"type":234},"2022-02-16",{"date":238,"type":224},"2027-02",{"name":5,"class":6},12]